This web site is not optimized for Internet Explorer 6. You may notice
decreased functionality compared to other web browsers. Please follow the
link below to upgrade to a new version of Internet Explorer.

The "Yes" link below will take you out of the Abbott Laboratories family of websites.
Links which take you out of Abbott Laboratories worldwide web sites are not under the
control of Abbott Laboratories, and Abbott Laboratories is not responsible for the
contents of any such site or any further links from such site. Abbott Laboratories is
providing these links to you only as a convenience, and the inclusion of any link does
not imply endorsement of the linked site by Abbott Laboratories.

Do you wish to leave this site?
 
Coronary Drug Eluting Stents

XIENCE PRIME Everolimus Eluting Coronary Stent System

Indications & Important Safety Information ››
 

 

Overview

xienceAdvancing Superior* Outcomes


Introducing XIENCE PRIME - The next generation in the XIENCE family engineered to deliver the superior outcomes of XIENCE V. With the same efficacious low dose Everolimus, biocompatible fluorinated copolymer, and enhanced Cobalt Chromium MULTI-LINK 8 design, superiority* is in its very nature.

 

 

 

 


 

*Xience V has demonstrated statistical superiority against Taxus Express in the primary endpoints of SPIRIT IV, SPIRIT III, and SPIRIT II in target lesion failure, in segment late loss, and in-stent late loss, respectively. Source: SPIRIT IV 1-year results, Gregg Stone. TCT 2009 and data on file at Abbott Vascular.

Specifications

A Heritage of Stent Design and Innovation

 Superior* outcomes defined by consistency in key stent components
Trusted CoCr Technology:
  • Outstanding strength and flexibility
  • Over 2.5 million1 CoCr MULTI-LINK stents implanted worldwide
CoCr 
Heritage of MULTI-LINK Leadership:
  • Proven design with optimal scaffolding and conformability
  • Over 8 million2 MULTI-LINK stents implanted through seven generations of market leadership
heritage of multi-link leadership 
Same efficacious low dose of Everolimus as XIENCE V  everolimus
Same biocompatible and mechanically dynamic polymer as XIENCE V  xience

*Xience V has demonstrated statistical superiority against Taxus Express in the primary endpoints of SPIRIT IV, SPIRIT III, and SPIRIT II in target lesion failure, in segment late loss, and in-stent late loss, respectively. Source: SPIRIT IV 1-year results, Gregg Stone. TCT 2009 and data on file at Abbott Vascular.
1. Includes ML VISION, ML MINI VISION, XIENCE V and PROMUS as of 2009. Data on file at Abbott Vascular.
2. Includes MULTI-LINK, ML DUET, ML TRISTAR, ML TETRA, ML PENTA, ML ZETA, ML VISION, ML MINI VISION, XIENCE V and PROMUS as of 2009. Data on file at Abbott Vascular
All tests performed by and data on file at Abbott Vascular.

 

Designed for Outstanding Deliverability

flexibility Flexibility
Advanced MULTI-LINK design with more** flexible connecting link
 conformability Conformability

 

Cobalt Chromium MULTI-LINK 83 design for optimal strength and scaffolding

 safety  Safety

 

Exceptionally short balloon tapers designed to minimize vessel injury4

 deliverability  Deliverability

 

Innovative catheter design for faster** deflation times and smooth rounded tip for exceptional tracking

 

3. MULTI-LINK 8 is the bare metal platform for XIENCE PRIME.
4. Lee DP, et al. Optimizing clinical outcomes with intracoronary stenting. The importance of minimizing vessel injury. Stent 2000, Vol. 3, No.1.
** As compared to XIENCE V. Tests performed by and data on file at Abbott Vascular.

Ordering Information

International XIENCE PRIME product numbers

XIENCE PRIME Ordering info

AP2932840 Rev. B

 

Indications and Important Safety Information

Top

Top